Peer Review reports
From: A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data
| Original Submission | ||
|---|---|---|
| 18 May 2023 | Submitted | Original manuscript |
| Resubmission - Version 2 | ||
| Submitted | Manuscript version 2 | |
| 11 Jun 2023 | Reviewed | Reviewer Report - Kittinun Leetanaporn |
| 13 Jun 2023 | Reviewed | Reviewer Report - Naglaa Elabd |
| 18 Jun 2023 | Reviewed | Reviewer Report |
| 30 Jun 2023 | Author responded | Author comments - Yamin Shu |
| Resubmission - Version 3 | ||
| 30 Jun 2023 | Submitted | Manuscript version 3 |
| 14 Jul 2023 | Reviewed | Reviewer Report - Kittinun Leetanaporn |
| 19 Jul 2023 | Reviewed | Reviewer Report - Naglaa Elabd |
| Resubmission - Version 4 | ||
| Submitted | Manuscript version 4 | |
| Publishing | ||
| 20 Jul 2023 | Editorially accepted | |
| 11 Aug 2023 | Article published | 10.1186/s12885-023-11201-w |
You can find further information about peer review here.